Ki67-positive. The target cells underwent further proliferation following the second treatment with UA and were transiently arrested by 5-FU treatment at G0/G1 after UA. Conclusions: The target cells are slow-cycling cells, resistant to 5-FU treatment and have the capacity to undergo further proliferation following a second insult with UA. These data suggest the presence of a distinct population of cells that can regenerate the S3 segment in UA-induced ARF.
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Nephron Exp Nephrol 2008;109:e57-e70 e58 these models [5, 6] . Even if intrinsic PT cells are the main contributors to tubule regeneration, it is not clear whether normally quiescent PT cells undergo dedifferentiation and acquire the ability to extensively proliferate after acute tubular damage [7] in a process commonly referred to as epithelial-mesenchymal transformation, or whether the tubules harbor stem/progenitor cells that could play a significant role in the tubular regeneration in the S3 segment. Thus far, three groups have reported the presence of adult PT progenitor cells in rats [8] [9] [10] . Although CD133 in human [11] , Oct4 in rat [10] and Sca-1 in mouse [12] have been used to identify renal stem/progenitor cells, the behavior of tubular progenitor cells especially in the S3 segment in vivo under normal conditions and after acute tubular injury has not been well studied.
We recently reported the kinetics of early regenerating PT cells in the S3 segment after acute tubular injury induced by low-or high-dose uranyl acetate (UA) in rats [13] . Low-dose UA (0.25 or 0.5 mg/kg) induced mild and focal PT depletion in the S3 segment. Some of the surviving cells scattered in the proximal three quarters of the S3 segment became thymidine-incorporating early regenerating PT cells and contributed to the repair of the focal PT injury. On the other hand, high-dose UA (2 or 5 mg/kg) induced acute renal failure (ARF) [13, 14] with marked necrosis of the S3 segment and complete PT cell depletion in three quarters of the S3 segment evident between days 4 and 5. The early regenerating cells originated in the distal area of the S3 segment from days 2 to 3. Upstream proliferation of PT cells occurred and this was almost complete by day 7. Based on these findings, we hypothesized that the early regenerating cells in the distal area of the S3 segment are the cellular source of regenerating cells after UA-induced ARF and a distinct population of PT cells in the S3 segment.
To further characterize the early regenerating cells, which we designated as the 'target cells', we examined whether the target cells exhibit a slow turnover as slowcycling cells [15, 16] and represent a real source of proliferating cells in the entire S3 segment. We then attempted to differentiate our target cells from PT progenitor-like cells in the S3 segment that could be identified as bromodeoxyuridine (BrdU)-label-retaining infrequently dividing cells under normal conditions and participated in the regeneration process after acute ischemic tubular injury [8] . In addition, we tested wheter the target cells are resistent to 5-fluorouracil (5-FU) treatment in vivo since 5-FU preferentially eliminates proliferating cells and spares non-cycling hematopoietic stem cells [17] . We also determined whether the target cells proliferate again after a second UA insult and examined the ultrastructure of the target cells. The results suggested that the target cells might be a distinct population of tubular cells that contribute to the regeneration of the S3 segment after UAinduced ARF.
Materials and Methods

Experimental Protocols
The experimental protocol was approved by the Ethics Review Committee for Animal Experimentation of the Hamamatsu University School of Medicine and complied with the NIH Guide for the Care and Use of Laboratory Animals. Eighty-one male Sprague-Dawley rats, weighing 180-230 g (SLC Co., Shizuoka, Japan), were provided with standard rat chow and drinking water ad libitum. A single intravenous injection of 4 mg/kg of UA was used to induce ARF with severe PT injury and marked elevation of the serum creatinine that peaked at day 5. A single intravenous injection of 0.25 mg/kg of UA was used to induce mild PT injury without elevation of the serum creatinine [13] . 3 H-Thymidine (100 Ci/100g body weight; Wako, Osaka, Japan) or 40 mg/kg of BrdU (Sigma Chemicals Co., St Louis, Mo., USA) were injected intraperitoneally at days 2, 2.5 and 3 following UA injection in order to track the early regenerating cells (i.e., the target cells) formed in the distal S3 segment in this ARF model [14] . Rats were anesthetized with diethyl ether and both kidneys were flushed with phosphate-buffered saline prior to removal. All experimental protocols performed are depicted in figure 1 .
Experimental Design 1 Rats injected with 3 H-thymidine were sacrificed at days 3, 5, 7 and 9 and at weeks 13 and 40 weeks following induction of ARF by injection of 4 mg/kg of UA. Kidney tissue was processed for autoradiography or immunohistochemistry for megalin. For autoradiography, methacarn-fixed sections were dehydrated, airdried, dipped in NTB2 emulsion (Eastman Kodak Co., Rochester, N.Y., USA) and placed in light-tight boxes. Following a 3-week incubation at 4 ° C, slides were developed (D19; Eastman Kodak) and counterstained with hematoxylin and eosin.
Experimental Design 2 To further examine phenotypic change of the target cells, 15 rats were injected with BrdU in order to label the target cells at days 2, 2.5 and 3 following administration of 4 mg/kg of UA. Kidneys were examined before and at days 3, 5, 7 and 21 and week 40 after UA injection and double immunostaining for BrdU and either megalin, aquaporin (AQP)-1, vimentin or PAX-2 was performed.
Experimental Design 3
In order to determine whether the target cells are the same cell population that could be labeled by BrdU under normal conditions, normal rats (n = 18) were intraperitoneally pulsed with BrdU daily for 1 week as reported by Maeshima et al. [8] . Two weeks after the last BrdU injection, rats were injected with 4 mg/ kg of UA to induce ARF (high-dose UA, n = 6) or with 0.25 mg/kg of UA to induce mild tubular injury (low-dose UA, n = 6). Rats were sacrificed just after BrdU-pulse labeling: 2 weeks after the e59 last BrdU labeling in normal rats and at days 3 and 7 after UA injection. The kidneys were processed for double immunofluorescence studies of BrdU and Ki67.
Experimental Design 4
To determine whether the target cells are 5-FU-resistant and have a capacity for proliferation and differentiation after withdrawal of 5-FU treatment, rats (n = 12) were injected with 5-FU (50 mg/kg) or vehicle control daily from days 0 to 4 following the injection of 4 mg/kg of UA. The target cells were BrdU labeled at days 2, 2.5 and 3 and kidneys were examined at days 5 and 7 after UA injection for immunohistochemistry (BrdU) or double-immunofluorescence studies (BrdU and Ki67, cyclin D1 or megalin).
Experimental Design 5
To examine whether the target cells can be reactivated by a second UA insult, BrdU was injected into rats (n = 9) to label the target cells at days 2, 2.5 and 3 after the administration of 4 mg/kg of UA. Five weeks after the first UA injection, the rats received a second injection of UA (4 mg/kg). Rats were sacrificed before and at 3 and 7 days after the second injection of UA and the kidneys were processed for double-immunofluorescence studies of BrdU and Ki67.
Immunohistochemistry
Kidneys were bisected through their longitudinal axis, fixed with either 4% paraformaldehyde or methacarn solution and embedded in paraffin. For immunohistochemistry, a standardized avidin-biotin complex technique was generally used on 4% paraformaldehyde-fixed sections. However, methacarn-fixed sections were used to detect BrdU (mouse anti-BrdU mAb 1: 1,000, Amersham International, Poole, UK) or megalin (goat polyclonal antimegalin antibody 1: 100, Santa Cruz Biotechnology, Santa Cruz, Calif., USA) as described previously [14] . The reaction product was visualized using the peroxidase-diaminobenzidine system for BrdU or the Vector red alkaline phosphatase substrate kit I (Vector Laboratories, Burlingame, Calif., USA) for megalin. Controls were composed of histochemical sections where the primary antibody was either omitted or replaced by normal serum of the relevant animal. Signals in both normal control and experimental sections were negative or negligible.
Immunofluorescence Studies Double-immunostaining of BrdU and either Ki67, cyclin D1, megalin, AQP-1, vimentin or PAX-2 was performed on 4% paraformaldehyde-fixed sections. Sections were incubated with either mouse anti-Ki67 mAb (Novocastra Laboratories, Newcastle upon Tyne, UK), rabbit polyclonal anti-cyclin D1 antibody (Santa Cruz), goat polyclonal anti-megalin antibody, rabbit polyclonal anti-AQP-1 antibody (Chemicon International Inc., Temecula, Calif., USA), mouse anti-vimentin mAb (Sigma, St Louis, Mo., USA) or rabbit polyclonal anti-PAX-2 antibody (Zymed, San Francisco, Calif., USA) followed by biotinylated donkey antimouse, anti-rabbit or anti-goat antibody as required. Vectastain ABC-AP reagent (Vector Laboratories) was then added and the Vector red alkaline phosphatase substrate kit I was used, which is visible as red fluorescence with a 540-to 596-nm band filter system. Sections were then heated in a microwave oven for 15 min in 0.01 M sodium citrate (pH 6.0) at 800 W followed by incubation with mouse anti-BrdU mAb. Following incubation with fluorescein isothiocyanate conjugated donkey anti-mouse IgG (Chemicon), sections were observed with an Olympus BX50 fluorescent microscope (Olympus, Tokyo, Japan) equipped with filter settings for Vector red product (red, filter cube U-MWIG), fluorescein isothiocyanate (green, filter cube U-MNIBA) and background autofluorescence (blue, filter cube U-MWU). Combined images were obtained using the fitted Olympus digital camera (DP70) and processed by DP manager software (Olympus).
Immunoelectron Microscopy
Pre-embedding immunoelectron microscopy was performed as described previously [18] to examine the target cells labeled by BrdU at days 2 (n = 3) and 2.5 (n = 3) after UA (4 mg/kg) treatment and at day 5 (n = 3) after UA with 5-FU treatment. Ultrathin sections were stained with lead citrate and examined with a JEM-1220 electron microscope (JEOL, Tokyo).
Morphometric Analysis
For morphometric analysis, the thickness of the layer of the outer stripe of the outer medulla (OSOM) was calculated with a 40 ! high-power objective. The slide was moved between the cortex-OSOM border and the OSOM-inner stripe of the outer medulla border and the number of grid lines of a 1-cm 2 eyepiece graticule counted (the graticule had 100 equidistant grid lines). Based on the number of grid lines at any site, the OSOM layer was arbitrarily divided into four zones of equal thickness (zones 1-4) under 400 ! magnification ( fig. 2 ) [13] .
In preliminary studies, we performed autoradiography of normal kidneys harvested 90 min after a single intraperitoneal injection of saline or experimental rats administered either saline or 
Statistical Analysis
Data are expressed as mean 8 SD. Differences between data sets were examined for statistical significance using analysis of variance (ANOVA) followed by Scheffé F test. A p level of ! 0.05 was accepted as statistically significant. All statistical analyses were performed using StatView (Abacus Concept, Inc., Berkeley, Calif., USA). Schematic drawing of the proximal tubule (S1 = segment 1; S2 = segment 2; S3 = segment 3; G = glomeruli). The layer of the outer stripe of the outer medulla was arbitrarily divided into four zones of equal thickness using an optical graticule with the zones designated as zone 1, zone 2, zone 3 and zone 4. In contrast, 'label-diluted cells' containing 5-10 grains/nucleus were rarely found in any S3 zone at day 3. 'Label-diluted cells' were increasingly found throughout zones 1-4 after day 5 with numbers decreasing by 13 weeks ( fig. 3 Ae-h, Bc). About 60% of the PT cells in the entire S3 segment were significantly labeled (at least 5 grains/nucleus) at day 7 when PT regeneration was almost complete ( fig. 3 C) .
After induction of ARF, most of the PT cells in S3 became negative for megalin, a marker of mature PT phenotype (data not shown), including the 'label-retaining cells' in zone 1 at day 3 ( fig. 3 Ai). 'Label-diluted cells' in zones 2-4 became positive for megalin as early as day 7 ( fig. 3 Aj) with almost all PT cells in S3 exhibiting megalin staining by week 13. Of note, some 'label-retaining cells' at the far end of the S3 segment were negative for megalin and present within tubules containing megalin-positive PT cells at weeks 13 and 40 ( fig. 3 Ak, Al).
Phenotypic Change of the Target Cells
The results for the expression of megalin, AQP-1, vimentin or PAX-2 in BrdU-labeled target cells in zone 1 are listed in table 1 . Under normal conditions almost all PT cells in zone 1 were positive for megalin and AQP-1 that is an additional marker of mature PT phenotype. However, it was not clear whether there were some cells that were negative for megalin at the transition zone between the PT and the thin descending limb of Henle. After induction of ARF, BrdU-labeled target cells became negative for megalin and AQP-1 as early as day 3 ( fig. 4 A) and with positive staining for megalin and AQP-1 returning by day 21 ( fig. 4 B) .
Under normal conditions all PT cells were negative for vimentin and PAX-2. However, some cells in the thin descending limb of Henle and collecting duct were positive for PAX-2 (data not shown) as previously reported [19] . After induction of ARF, the target cells expressed vimentin as early as day 3 ( fig. 4 C) and became negative for vimentin by day 21 ( fig. 4 D) . The target cells were positive for PAX-2 with a nuclear expression pattern evident as early as day 3 ( fig. 4 E) and became negative for PAX-2 by day 21 ( fig. 4 F) .
Relationship between Target Cells and Label-Retaining Cells Labeled under Normal Conditions
The 7-day period of intraperitoneal BrdU injections labeled PT cells throughout the S3 segment in normal rats with an approximately equal number of BrdU+ cells found in each S3 zone 2 weeks after the last BrdU administration ( fig. 5 Aa, Ab).
When BrdU-labeled rats were injected with 4 mg/kg UA, which induced severe ARF, BrdU-label-retaining cells were distributed throughout all S3 zones at day 3 following UA injection and the number of BrdU-label-retaining cells in all zones was markedly reduced due to the severe tubular damage evident by day 7 ( fig. 5 Ac, Ad). A significant number of PT cells in zone 1 were positive for the cell proliferation marker Ki67 at day 3. Ki67+/BrdU+ PT cells constituted only 12.5% of total Ki67+ PT cells in zone 1 at day 3 ( fig. 5 Ac, Ba) and were not found significantly in any zone at day 7 ( fig. 5 Ad), suggesting that most Ki67+-proliferating cells in UA-induced severe ARF are those cells that were not labeled by BrdU under normal conditions.
When mild PT injury in the S3 segment was induced by 0.25 mg/kg of UA [13] in BrdU-labeled rats, a signifi- 3 Some cells were PAX-2+ in the thin descending limb of Henle. 4 Some BrdU+ cells were also PAX-2+ at the transition zone between the PT and the thin descending limb of Henle.
Distinct Population of Cells and Regeneration in S3 Segment
Nephron Exp Nephrol 2008;109:e57-e70 e63 cant number of Ki67+/BrdU+ PT cells was found at day 3 (Ki67+/BrdU+ PT cells expressed as a percentage of total Ki67+ PT cells: 26.1% in zone 1, 41% in zone 2, 53% in zone 3 and 47.6% in zone 4 at day 3; fig. 5 Ae, Bb). This suggests that approximately half of the Ki67+ cells in the S3 segment in mild UA-induced tubular damage are cells that are labeled by BrdU under normal conditions. Although the number of Ki67+-proliferating cells diminished at day 7, the number of BrdU+ cells increased and this is likely to be the result of cell division ( fig. 5 Af).
Effect of 5-FU on the Target Cells
We tested the effect of 5-FU on the target cells. When BrdU was administered to vehicle-treated rats following 4 mg/kg UA injection, the BrdU+ cells were distributed throughout all S3 zones at day 5 after UA ( fig. 6 Aa). At day 7, the distribution pattern of BrdU+ cells was unchanged but the number of BrdU+ cells seemed to increase and the staining intensity of BrdU became weaker ( fig. 6 Ab). On the other hand, the distribution of BrdU+ cells was restricted to zone 1 in 5-FU-treated rats at day 5 after UA ( fig. 6 Ac) and the number of BrdU+ cells was significantly higher in zones 2-4 at day 5 in vehicle-treated rats compared to 5-FU-treated rats ( fig. 6 B) . Following withdrawal of 5-FU, the number of BrdU+ cells increased significantly in zones 2-4 at day 3 (7 days after UA injection) relative to their number at day 5 in 5-FU-treated rats ( fig. 6 Ad, 4 B) .
Double immunostaining studies showed that 42.5% of BrdU+ cells were also Ki67+ in zone 1 in vehicle-treated rats at day 5 ( fig. 6 Ca), but only 7.7% of BrdU+ cells were Ki67+ in 5-FU-treated rats at day 5 ( fig. 6 Cb). However, 32% of BrdU+ cells throughout all zones were positive for Ki67 in 5-FU-treated rats at day 7 (3 days after withdrawal of 5-FU; fig. 6 Cc). In 5-FU-treated rats, some BrdU+ cells in zone 1 were positive for cyclin D1, a marker of G1 
Effect of Repeated UA Administration on the Target Cells
Five weeks after the first injection of UA (4 mg/kg), BrdU-label-retaining target cells were significantly higher in zone 1 than the other zones ( fig. 7 Aa). Three days after the second injection of UA (4 mg/kg), a significant number of Ki67+ proliferating PT cells was found in all zones and about 16% of BrdU-label-retaining cells became Ki67+ ( fig. 7 Ab, B) . At day 7, the number of BrdU+ cells in all zones was increased ( fig. 7 Ac), thereby suggesting cell division of the target cells.
Immunoelectron Microscopic Appearance of the Target Cells
At days 2 and 2.5 after 4 mg/kg of UA, ultrastructural examination showed the presence of BrdU-labeled target cells on the tubular basement membrane as either isolated tubular cells ( fig. 8 A, B) or as a pair of tubular cells ( fig. 8 C) . These cells contained large nuclei, scanty cytoplasm, reduced or absent brush border and no basolateral infoldings, thereby suggesting a dedifferentiated or relatively undifferentiated tubular cell phenotype ( fig. 8 A-C) . They were not associated with particular cells surrounding the tubules such as capillary endothelial cells and fibroblast-like cells ( fig. 8 A-C) . Some of them were located at the transition zone between the PT and the thin descending limb of Henle, and had a similar morphology to other cells in zone 1 ( fig. 8 B) .
The target cells in the distal area of the S3 segment at day 5 after UA with 5-FU treatment showed features similar to those at days 2 and 2.5 after UA among necrotic tubular cells ( fig. 8 D) .
Discussion
In the present study, the target cells indicating early regenerating cells were found at the distal area of the S3 segment of the nephron and were followed during the process of tubular regeneration that follows UA-induced ARF. According to our previous study [14] , within 3 days after administration of 4 mg/kg UA almost all proliferating PT cells were observed only in zone 1 of the S3 segment. In this study, the proliferating PT cells were only labeled with 3 H-thymidine during days 2-3 such that 3 Hthymidine-labeled PT cells originated mainly from zone 1. We found that the number of 'label-retaining cells' containing 1 20 and 1 40 grains/nucleus was significantly higher in zone 1 than in other zones at day 3. 'Label-retaining cells' were still identified in zone 1 up to 40 weeks and their numbers were constant from day 5 to 13 weeks. In contrast, the 'label-diluted cells' containing 5-10 grains/nucleus, which seem to be progeny cells of 'labelretaining cells', were only occasionally found in the entire S3 segment at day 3 but were distributed increasingly throughout the entire S3 segment after day 5. Their numbers were similar in all S3 zones at day 7 when epithelial reconstitution was almost complete, thereby suggesting that progeny cells in all S3 zones underwent similar proliferation. Taking into consideration that not all the target cells that were early proliferating PT cells in zone 1 could be labeled by the present method and that the signal from some 'significantly labeled cells' could be lost by day 7, our results indicate that about 60% of PT cells in the S3 segment were 'significantly labeled cells' at day 7. This suggests that the majority of the regenerating cells in the S3 segment originate from the target cells in zone 1.
In the present model, it is not clear how many times the target cells underwent cell division and took up 3 Hthymidine during the 3 episodes of pulse-labeling for 24 h. The mean cell cycle time was reported to be 10-12 h during the early regenerating epidermis in mice [20, 21] . If the target cells symmetrically divided 2-3 times during the period of 3 H-thymidine pulse-labeling, then it is unlikely that PT cells continued to contain 1 40 grains after day 3, and this suggests that some target cells may asymmetrically divide 2-3 times into new cells that stop cell cycle similar to progenitor-like cells. These findings also suggest that the target cells probably have a slow turnover as slow-cycling cells and are potentially the real source of regenerating cells after UA-induced ARF.
The target cells were negative for the mature PT marker megalin at day 3 but 'significantly labeled cells' in zones 2-4 began to express megalin after day 7 and 'label-retaining cells' in zone 1 expressed megalin by week 13. Some 'label-retaining cells' at the far end of the S3 segment were megalin-negative, but these were located within tubules with megalin-positive PT cells at 13 and 40 weeks after ARF. This suggests that the 'label-retaining' target cells are PT cells or intermediate cells between the PT and the thin descending limb of Henle and might maintain a relatively undifferentiated phenotype under normal conditions.
We further examined the phenotypic change in BrdUlabeled target cells ( table 1 ) . The target cells were negative for the mature PT marker AQP-1 at day 3 after the induc- On the other hand, the target cells transiently expressed the mesenchymal marker vimentin and the embryonic marker PAX-2. PAX-2 is a transcription factor that is essential for kidney development, promoting the transition of mesenchyme to epithelium [22] . PAX-2 has been reported to be transiently expressed in PT cells during the initial phase of recovery from ARF in both mice [23] and rats [24] . These findings suggest that the target cells could transiently dedifferentiate (and possibly acquire progenitor cell markers) before generating new PT cells.
Maeshima et al. [8] reported that a distinct population of BrdU-label-retaining, infrequently dividing cells exists scattered in the S3 segment of the normal rat kidney and that these cells behave as renal progenitor-like cells in ischemic renal tubular injury in rats. They stated that there is no current consensus as to whether these labelretaining cells with the capacity to regenerate should be referred to as unipotent stem cells or simply as cells that have retained proliferative potential [25] . In the present study, following BrdU labeling under normal conditions, we also found a large number of BrdU-label-retaining cells throughout all zones of the S3 segment with half of BrdU-label-retaining cells having the potential to proliferate following mild tubular injury induced by low-dose UA. However, the BrdU-label-retaining cells could not contribute to the source of regeneration after the induction of ARF (severe tubular injury) by high-dose UA. Most of the BrdU-label-retaining cells in zones 2-4 of the S3 segment should die following exposure to high-dose UA. Although there were still a significant number of BrdU+ PT cells in zone 1 at day 3 that survived UA nephrotoxicity, most of them did not exhibit proliferative activity as assessed by Ki67 immunostaining. These findings suggest that our target cells in zone 1 are also a distinct cell population, which may be different from the population of progenitor-like cells labeled under normal conditions. There is evidence that 5-FU preferentially eliminates proliferating cells, though it spares non-cycling stem cells that have a high capacity to generate other stem/progenitor cells and daughter cells in hematopoietic cells [17] . In the present study, rats treated with 5-FU from days 0 to 4 exhibited BrdU-labeled target cells located predominantly in the distal quarter of the S3 segment at day 5. These cells were negative for Ki67 (marker for S phase) while some of them were positive for cyclin D1 (marker for G1 phase), suggesting that 5-FU arrests the target cells at G0/ G1. After withdrawal of 5-FU, some BrdU-labeled target cells were Ki67+ and their progeny were positive for megalin and distributed in a proximal direction after day 7, suggesting that the target cells were resistant to 5-FU and maintained their proliferative capacity. There are some reports evaluating cell proliferation by BrdU under 5-FU treatment in vivo [26] and BrdU may be adequately incorporated by cells in S-phase during 5-FU treatment. The serum level of BrdU was reported to be cleared within 2 h after intravenous administration and about 3 h after oral administration in dogs [27] . Though we administered BrdU by intraperitoneal injection in rats, it is conceivable that the BrdU+/Ki67+ cells in both vehicle-and 5-FU-treated rats represent cells that were labeled with BrdU during days 2-3 plus a few hours and became Ki67+ in the last hours before the rats were killed at days 5 or 7. However, it is not possible to assess whether a BrdU+ cell has just been labeled or is a descendant of a previously labeled cell. It is not known if epithelial stem/progenitor cells show the same behavior against 5-FU like hematopoietic stem cells, although it is reported that 5-FU does eliminate proliferating epithelial cells such as retinal pigment epithelial cells [28] and lens epithelial cells [29] . Our data support the concept that a small pool of cells in the distal region of S3 may divide once after injury and then retain the label for a prolonged period of time, suggesting that these cells may in some way be unique.
In the present study, about 16% of the target cells which were labeled by BrdU after the first UA insult could also proliferate after a second UA insult ( fig. 5 ) , suggesting that the target cells maintain the capacity to proliferate after the renewal of S3 segment.
Ultrastructural examination of the target cells in zone 1 showed isolated or paired cells among PT cells on the undisrupted tubular basement membrane at days 2 or 2.5, indicating no invasion from outside the tubules. They exhibited morphologic features of dedifferentiated/undifferentiated cells such as a small brush border, large nuclei and fewer cytoplasmic organelles, so that they were compatible with a progenitor cell population [30] . The morphology of some of the target cells localized at the transition zone between the PT and the thin descending We assume that the proliferation potential of PT cells in the S3 segment is not limited to a small population such as progenitor-like cells after acute PT injury. This may be applicable for the regeneration of the S3 segment after less severe PT injury induced by low-dose UA [13] . It has even been recently reported that cycling cells in the S3 segment of the juvenile healthy rat are differentiated PT cells [31] . However, it is also possible that high-dose UA can activate the target cells that might be the normally dormant progenitor-like cells in the distal S3 area. This seems to be similar to the liver regeneration system where several models of liver injury in rats show that the liver contains a population of stem cells that enable it to regenerate and act as a backup mechanism for liver regeneration when the ability of hepatocytes to proliferate via compensatory hyperplasia is compromised [32] . It is thus necessary to investigate whether the target cells act in a similar way after different kinds of injury such as ischemia/reperfusion injury.
In summary, the major findings of our study are as follows. [8, 25] , which can be labeled under normal conditions. Taken together, our findings suggest that there is a distinct population of tubular cells in the distal area of the S3 segment, which may be activated and proliferate if the replicative capacity of PT cells in the S3 segment is severely compromised. However, it remains unclear whether the target cells are true progenitor-like cells or merely dedifferentiated PT cells.
